Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.36 USD
-0.13 (-0.96%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $13.35 -0.01 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TAK 13.36 -0.13(-0.96%)
Will TAK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Other News for TAK
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
Big pharma rally after J&J earnings
3 Biotech Stocks For The Second Half Of 2024
Takeda Announces New Assignments of Directors
GLOBAL BRIEFING: Stocks to open higher after US tech stocks recover